False Positive Findings of [18F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels
BackgroundPET-CT using prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals labeled with 68Ga or 18F has emerged as the most sensitive staging tool in prostate cancer (PC). Nonetheless, the occurrence of false positive (FP) findings presents a major concern of this approach. In t...
Main Authors: | Marina Orevi, Simona Ben-Haim, Galith Abourbeh, Alexandre Chicheportiche, Eyal Mishani, Vladimir Yutkin, Ofer N. Gofrit |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Surgery |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.943760/full |
Similar Items
-
Case Report: 18F-PSMA-1007 PET/CT Avid Solitary Penile Metastasis of Castration-Resistant Prostate Cancer With a PSA of 0.072 ng/ml
by: Yongliang Li, et al.
Published: (2022-04-01) -
Diagnostic Role of <sup>18</sup>F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review
by: Salam Awenat, et al.
Published: (2021-03-01) -
The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer
by: Jun-jie Hong, et al.
Published: (2020-11-01) -
Application of 18F-PSMA-1007 PET/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels ≤ 0.5 ng/mL
by: Małgorzata Mojsak, et al.
Published: (2023-08-01) -
Comparison of [<sup>18</sup>F]PSMA-1007 with [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
by: Manuela A. Hoffmann, et al.
Published: (2022-03-01)